收费全文 | 126906篇 |
免费 | 31197篇 |
国内免费 | 1106篇 |
耳鼻咽喉 | 2671篇 |
儿科学 | 3769篇 |
妇产科学 | 3010篇 |
基础医学 | 6414篇 |
口腔科学 | 5452篇 |
临床医学 | 29813篇 |
内科学 | 28941篇 |
皮肤病学 | 3715篇 |
神经病学 | 15067篇 |
特种医学 | 4350篇 |
外国民族医学 | 1篇 |
外科学 | 21673篇 |
综合类 | 820篇 |
一般理论 | 45篇 |
预防医学 | 16873篇 |
眼科学 | 2698篇 |
药学 | 3403篇 |
中国医学 | 59篇 |
肿瘤学 | 10435篇 |
2023年 | 5198篇 |
2022年 | 1216篇 |
2021年 | 3351篇 |
2020年 | 5792篇 |
2019年 | 2861篇 |
2018年 | 7806篇 |
2017年 | 7961篇 |
2016年 | 8522篇 |
2015年 | 8675篇 |
2014年 | 11377篇 |
2013年 | 13497篇 |
2012年 | 5859篇 |
2011年 | 5651篇 |
2010年 | 7914篇 |
2009年 | 10034篇 |
2008年 | 5121篇 |
2007年 | 4106篇 |
2006年 | 5170篇 |
2005年 | 3748篇 |
2004年 | 2967篇 |
2003年 | 2584篇 |
2002年 | 2363篇 |
2001年 | 2466篇 |
2000年 | 1692篇 |
1999年 | 2155篇 |
1998年 | 2300篇 |
1997年 | 2035篇 |
1996年 | 2156篇 |
1995年 | 1865篇 |
1994年 | 1262篇 |
1993年 | 1076篇 |
1992年 | 1087篇 |
1991年 | 975篇 |
1990年 | 863篇 |
1989年 | 832篇 |
1988年 | 762篇 |
1987年 | 638篇 |
1986年 | 566篇 |
1985年 | 534篇 |
1984年 | 459篇 |
1983年 | 453篇 |
1982年 | 362篇 |
1981年 | 303篇 |
1980年 | 236篇 |
1979年 | 231篇 |
1978年 | 267篇 |
1977年 | 226篇 |
1976年 | 181篇 |
1974年 | 200篇 |
1973年 | 164篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献